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The current status of phage therapy approaches is reviewed and possible hurdles to a practical medical
application of bacteriophages in Western countries are identiﬁed as discussed at a recent EMBO
meeting on ‘‘Viruses of Microbes’’ in Brussels. In view of the growing antibiotic resistance crisis, a
coordinated effort by the public health sector is needed to evaluate the potential of phage therapy as an
adjunct to antibiotics.
& 2012 Elsevier Inc. All rights reserved.The author has attended three conferences over the last half
year dealing with phage therapy (PT) as a major conference topic:
the First Bacteriophage meeting at Oxford University, the Banbury
conference at Cold Spring Harbor Laboratory and the Brussels
EMBO meeting on Viruses of Microbes II (VoM II). Further
bacteriophage conferences with focus on PT took place (Tbilisi,
Georgia) or will take place in 2012 (Oxford, UK). One could
conclude that phage therapy became a subject attracting sub-
stantial attention. To a certain degree, this perception reﬂects
indeed a new reality: at the Banbury meeting S. Stibitz from the
Food and Drug Administration (FDA) explained the regulatory
standards requested by FDA for phage approval; at VoMII J.
Scheres, from the Managing Board of the European Centers for
Disease Control (ECDC) and chairman of the ‘‘EurSafetyHealthnet’’
on antibiotic resistance and hospital infections gave his view
on PT.
The FDA sees the following advantages with phage: Phages are
highly speciﬁc, they work where alternatives have failed, are self-
dosing, can be highly puriﬁed, and are generally non-toxic. On the
negative side S. Stibitz listed phages as highly speciﬁc such that
PT requires the identiﬁcation of the bacterial pathogen. Resistance
might also develop against phages. The pharmacokinetics of
phages might not be ideal and immune response will limit the
re-use of phages after intravenous use. With respect to the proﬁle
for therapeutic phages the FDA desires that only obligatory lytic,
non-transducing phages are used which do not avoid clearance by
the body and use preferentially virulence factors as receptors
(such that resistant mutants will be less virulent) and are derived
from the natural environment. For the FDA the phage product
characterization should comprise the DNA sequence of each
phage, a characterized seed lot system and growth media raising
concerns about prion diseases must be avoided. Toxicity testing in
an animal system, sterility and stability testing are also needed.
Dr. Stibitz speciﬁed that the use of phage cocktails is fully
accepted by the FDA if this increases the treatment spectrum,
but each phage included must show activity and stability. As
phages are considered relatively low risk when the FDA selection
criteria are met, not very high numbers of treated humans are
needed to demonstrate their safety. According to FDA registered
controlled human clinical trials are the gold standard for thell rights reserved.efﬁcacy evaluation of phages. He underlined that the FDA is
interested in PT and wants to develop pragmatic regulatory
guidelines for phage use. Dr. Scheres stressed that several phage
therapy trials should be conducted against different infectious
diseases not to discard PT on the basis of a single negative trial
outcome.
That health authorities expressed their opinion on PT is a new
trend. However, there are also aspects that have not changed. The
PT speakers are more or less the same, they represent only a
handful of institutions and they deliver relatively static pictures.
No newcomers, industrial or academic, were attracted to this
scene. D. Harper, chief scientiﬁc ofﬁcer from Ampliphi Bios-
ciences/Biocontrol Ltd UK, who was instrumental in organizing
a small controlled clinical trial on Pseudomonas infections in otitis
externa (‘‘swimmers’ ear’’) (Wright et al., 2009) came up with the
same messages as in previous conferences. According to his
evaluation (Parracho et al., 2012), the regulatory hurdles for a
medical application of phages are high, the ﬁnancial investments
are substantial (essentially not very different from the develop-
ment of a new antibiotic with a minimum of US$ 10–50 million),
and the only way for regulatory agencies and the medical
community to accept phage therapy is via controlled clinical
trials. At the VoM I meeting in Paris, the author, working at the
Nestle´ Research Center (NRC), demonstrated the slow progress of
human safety studies with a T4-like phage cocktail by presenting
two small safety trials in healthy adults in Switzerland (Bruttin
and Bru¨ssow, 2005) and Bangladesh (Sarker et al., in this issue),
which were followed by two small safety trials in healthy children
of decreasing age in Bangladesh. The latest trial was on the safety
of oral phage cocktails in children hospitalized with a micro-
biologically conﬁrmed E. coli diarrhea, the genetic safety of T4-like
phages being studied by DNA sequencing. At VoMII A. Gorski from
the Institute of Immunology and Experimental Therapy, Wroclaw/
Poland presented compassionate PT approaches in Polish patients
where antibiotic treatment had failed. These data were also
recently published (Mie˛dzybrodzki et al., 2012). This report
summarizes the results of phage therapy obtained in various
clinical settings providing details on duration and route of phage
administration and type of infections with statistical analysis.
Overall, a good response was observed in 40% of the patients with
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153 analyzed cases required termination of the treatment due to
adverse events that could be related to use of the phage prepara-
tion. The authors are aware that ﬁnal proof for the efﬁcacy of
phage therapy can only be obtained by controlled clinical trials,
but so far lacked the funding for conducting such trials. Always
present, although this time with less media attention than at VoM
I was the Tbilisi Eliava Institute, representing the wealth of PT
experience acquired in the former Soviet Union (Chanishvili,
2012). The Eliava Institute has started to publish their studies in
western scientiﬁc journals e.g. (Kvachadze et al., 2011) and has
compiled past experience and trials in a book (Chanishvili and
Sharp, 2009). However, a large and well-designed prevention trial
with Shigella phages conducted in children from Tbilisi in the
1960s, which fulﬁls the quality requirements of modern placebo-
controlled randomized clinical trials ( Sulakvelidze et al., 2001), is
to date only documented by a single table in an abstract. During
the ﬁrst Tbilisi International phage meeting, the author was told
that the original data were irretrievably lost in the archives of
the KGB.
On a factual side, PT is a medical reality in Russia where a
number of companies, the most prominent being Microgen, sell a
large list of different phage cocktails for diverse bacterial infec-
tions and medical indications. Since the late 1980s these phage
preparations are registered medicines in Russia and are sold as
over-the-counter products at pharmacies in Russia, Belarus and
the Ukraine. Microgen did not publish details about their phage
cocktails or data on the clinical efﬁcacy of their products. It is thus
difﬁcult to assess the value of these phage preparations for the
claimed applications. For this reason, the Nestle´ Research Center
has taken the E. coli phage preparation from Microgen as a
treatment arm in the clinical trial conducted at the International
Center for Diarrheal Disease Research in Dhaka/Bangladesh
(ICDDR,B). The Microgen product is tested in parallel with the
NRC T4-like phage cocktail and a placebo group. The hosts of the
VoM II meeting, the Belgian military in collaboration with the
microbial biotechnologists from the universities of Leuven, Ghent
and Brussels are also conducting a controlled clinical trial in burn
patients. However, at this meeting they did not report safety or
efﬁcacy data from this ongoing clinical trial and the investigators
mentioned only some problems with phage bioavailability in the
panel discussion. To date the Belgian researchers have published
only a detailed description of their phage cocktail (Merabishvili
et al., 2009), their difﬁculty to get authorization for a clinical trial,
and on regulatory hurdles in the current Medicinal Product Legal
Framework (Verbeken et al., 2007, 2012). At the conference, the
Belgian researchers suggested that patents are a problem for
companies that might want to invest in the ﬁeld of PT. Some
companies like Intralytics in the USA developed anti- E. coli and
anti-Listeria phage cocktails for the food industry, obtained
patents and gained FDA approval for their Listeria phage cocktail
as a food additive (http://intralytix.com/) probably to avoid drug
regulation. Along this line, E. Kutter from Evergreen College in
Olympia/USA apparently proposed to investigate in Washington
State to implement PT in the context of natural food. In discus-
sions at the conference, the author heard that EFSA has requested
additional safety data for this food application of phages as
processing aids from European companies working in that ﬁeld.
At the Banbury meeting, Gangagen, an Indian-US company
dedicated to PT was also prominently present as a conference
sponsor. Initially, Gangagen has, like Intralytix (Abuladze et al.,
2008), targeted E. coli O157 infections in food with phages, but is
now looking more into lysis-deﬁcient phages (Paul et al., 2011),
phage tails and phage-derived proteins with anti-bacterial prop-
erties produced by genetic engineering approaches (George et al.,
2012).All these activities might seem a lot particularly when includ-
ing the scientiﬁcally well documented phage lysins as a type of PT
(Fischetti, 2008). However, the ﬁeld visibly failed to attract new
groups or investors to PT. At VoM II, P. Barrow represented the
publication-wise well-documented British veterinary PT tradition
(Atterbury et al., 2007) going back to the seminal work of H. W.
Smith in the 1980s (Smith et al., 1987), he also reported their
interest to extend PT to Vibrio cholerae infections in humans. A
relative newcomer to the ﬁeld is L. Debarbieux from Paris Pasteur
Institute, co-organizer of VoM I, who published some of the best
mouse model data on PT (Debarbieux et al., 2010; Maura et al.,
2012; Morello et al., 2011). Yet, he is relatively isolated at Pasteur:
despite the fact that PT was nearly 100 years ago invented at
Pasteur Institute by F. D’He´relle, the discoverer of phages, this
Institute is today not backing PT with a large research project.
Particularly striking is the absence of several key groups from
conferences covering PT, namely the pharmaceutical industry and
the medical community. It is not clear whether the pharma sector
has analyzed the situation and came to the conclusion that
investments are not proﬁtable, does not want PT to compete with
antibiotics, is not familiar with phage approaches, or lacks the
competence in the ﬁeld. The pharmaceutical industry is, from its
origin, a brainchild of chemistry and natural phages might not be
sufﬁciently deﬁned pharmaceutically to make them tools of their
trade. Yet biological approaches are familiar to the branch of the
pharmaceutical sector dealing with biologicals and vaccines. Food
industry in contrast has a long standing interest in phage biology;
this derives from the deleterious impact of bacteriophages on
food fermentation with deﬁned starter bacteria. Especially in the
dairy industry, phage infections can lead to fermentation delays
or even the loss of the product. Traditionally, the dairy industry
has maintained substantial knowledge in phage biology for their
industrial activity (Labrie et al., 2010; Sturino and Klaenhammer,
2006). This is also the case for the author who, for years, has
worked on dairy phages at NRC with the aim to protect starter
bacteria in yoghurt and cheese fermentation from phage attack
(Bru¨ssow, 2001). Pharma industry lacks this background and
might feel uneasy with phages.
Even more surprising is the relative absence of interest in PT
from the medical side of the community. At the Banbury phage
conference, B. Kreiswirth (Public Health, Univ New Jersey)
reported on problems he faced at an intensive care unit with
patients infected by antibiotic-resistant Klebsiella strains, and B.
Biswat (Fort Detrick, Maryland) reported on the applications of PT
in military medicine. A few military physicians and infectious
disease specialists were also present at VoM II without, however,
widely publicizing their views. In spring 2012, the WHO declared
the beginning of the end for the antibiotic era and designed the
dark spectre of trivial bacterial infections that will escape from
antibiotic control. Antibiotic resistance is a subject that ﬁlls the
columns of medical and scientiﬁc journals and has also reached
the lay press. However, this community has not yet identiﬁed PT
as a potential answer to the antibiotic crisis. I will illustrate this
attention deﬁcit with a recent event: In summer 2011, Germany
has experienced the greatest epidemic outbreak of food-borne
enterohemorrhagic E. coli infections (Muniesa et al., 2012). In
EHEC infections antibiotic treatment is medically counter-
indicated since earlier observations suggested that it could
activate the expression of the Shiga toxin. It turned out that the
German outbreak strain was not a usual EHEC strain, but was
nevertheless highly antibiotic resistant. Treatment of diseased
patients became a medical dilemma and led to a high lethality in
adult patients. A number of unproven interventions were
explored with variable success. Interestingly, three groups work-
ing in the PT ﬁeld had a phage that lysed the epidemic O104:H4
strain (Maura et al., 2012). L. Debarbieux had phages against this
Opinion / Virology 434 (2012) 138–142140strain because his animal model happens to use an enteroaggre-
gative O104 E. coli strain. NRC had an O104:H4 lysing strain
because we had established a T4-like phage collection against the
major diarrhea-associated E. coli serotypes, the O104 serotype has
been isolated from infantile diarrhea in tropical countries. In fact,
NRC offered this isolate to the German public health sector during
the epidemic. At VoM II the author saw a poster from M.
Merabishvili/Eliava Institute reporting similar phages from the
phage collection maintained by the Eliava Institute. Neither the
medical community nor the public health sector asked for these
phages during the outbreak. None of the scientiﬁc and medical
papers published during the outbreak mentioned PT as a potential
treatment. From this observation one could conclude that PT is
essentially not known in the Western medical community or not
taken seriously and dismissed as ‘‘Stalinistic cure’’ by the minority
who had heard about it. To get that attention it will be important to
publish controlled clinical trials of PT in major medical journals.
Those public health researchers who were aware about the
potential of phages from their own research work on phages
might have been concerned about the prospect that the thera-
peutical phage would activate the Shiga toxin expression in the
resident prophage harbored by the O104:H4 epidemic strain.
However, one should not blame medical practitioners for their
lack of knowledge about PT. The author has been a reviewer in
research calls from major Canadian and British grant agencies on
‘‘Alternatives to Antibiotics’’. The targets were scientists in coun-
tries where substantial applied phage research is still conducted.
PT proposals were a small minority and most came from groups
working in the ﬁeld of dairy microbiology or food safety.
A special case are phage lysins, pioneered by V. Fischetti at the
Rockefeller University. The approach was documented in a series
of high-proﬁle publications (e.g. Loefﬂer et al., 2001; Schuch et al.,
2002) and is at the same time covered by numerous patents; the
lead scientist is interested in commercial application of phage
lysins. Pertinent animal experiments were conducted and even
applied research was done to increase the bioavailability of the
phage enzymes in the animal body (Resch et al., 2011). Despite
this well-known research, the author is not aware that a single
controlled clinical trial has been initiated with phage lysins,
which leaves the scientiﬁc audience wondering why this
approach has not been picked up by the pharma sector.
Resistance development is apparently not a major problem with
phage lysins (only one recent report mentions a regrowth of the
pathogen, Schmelcher et al., 2012), but the rapid clearance of
these enzymes after oral or nasal application might represent a
hurdle for their commercialization.
What is needed to get PT into the clinical practice or – not to
anticipate a positive result- at least be clinically tested? In the
opinion of the author, phage biologists ﬁrst need to get involved
with basic questions of phage’s behavior in the human body. It is
probably true that phages like lambda and T4 today still represent
the best characterized biological systems. They owe this position
to the reductionist principle introduced by Max Delbrueck. Phage
biologists have investigated their objects of research under the
most simpliﬁed conditions. Phage biology became thereby the
cradle of molecular biology. However, molecular biology has now
reached a degree of maturity and has access to such powerful
analytical technologies that the reductionist principle has lost its
necessity and—I would argue—also its attractiveness. The natural
habitat of phage T4 and its target bacterium Escherichia coli is the
gut of higher animals including humans (Chibani-Chennouﬁ et al.,
2004). T4 and E. coli were workhorses of the molecular biology
revolution. However, when it comes to the gut, the biology of
E. coli is much less documented and that of T4 is practically non-
existing. Animal experiments with T4 and T7 phages in mice
conducted in several laboratories including NRC (Weiss et al.,2009) and Pasteur (Maura et al., 2012) revealed that we do not
understand the interaction between phages and their bacterial
host (E. coli) in their natural habitat (as far as laboratory mice
reﬂect this situation). Phage replication may be transient (but we
do not know why) or phages may replicate either modestly (in the
case of T4) or to very high titer (in the case of T7). However,
fecally excreted E. coli titers remain unaffected. Susceptible
bacterial cells and viable phage were isolated from the same fecal
sample. Animal experiments suggest several compartments for
E. coli cells in the gut with different phage susceptibilities which
are not fully described by the resistance development seen during
in vitro experiments. At VoM II, A. Buckling described experiments
exploring the limitation of PT by phage resistance development
(Hall et al., 2012). However, the above-mentioned mouse experi-
ments suggest that in vivo lysis of in vitro fully susceptible cells is
already a problem, probably reﬂecting our limited knowledge of
the physiological state of E. coli in the gut. All these observations
indicate that we simply do not understand the biology of phage-E.
coli interaction in their natural habitat, the gut. This simple
conclusion is shocking because it tells us that our wealth of
in vitro data about phage and E. coli does not allow us to predict
their normal ecological behavior. Brutally expressed, this means
that despite decades of research spent speciﬁcally on this system,
we do not understand its basic biology. However, the analysis and
comprehension of this system is not out of reach for current
research techniques. This was vividly demonstrated by Salmonella
molecular biologists investigating their research object in the gut
and the body of mice. In the opinion of the author we need
to attract talented researchers into investigating the in vivo
phage-E. coli interaction in the complexity of the mouse gut (or
mini pig gut if the effect of oral phage on diarrhea should be
studied). These studies will not only enrich our understanding of
these work horses of molecular biology at the next complexity
level, it will teach PT researchers how to achieve adequate
bioavailability and in vivo phage lysis. This issue is not a speciﬁc
problem for E. coli phages in the gut but a very similar lack of
knowledge also exists when it comes to the bioavailability and
in vivo lysis of Staphylococcus aureus and Pseudomonas aeruginosa
by the corresponding phages on the skin or in burn wounds. Since
these sites are accessible even in patients, such studies would not
depend on animal models and could be conducted with clinical
material taken directly from patients.
Different phage types are likely to display different in vivo
behavior as is already evident from the differences between T4
and T7 displayed in the mouse gut. These data will also increase
our knowledge about the pathogenesis of infectious diseases. In
fact, phages have in the past revealed a lot about the physiology
of the bacterial cell. It seems logical to anticipate that phages will
likewise reveal a lot about the pathophysiology of bacteria
infections in vivo.
However, the support of academic phage biologists will not yet
be enough to make PT a medical reality. The efﬁcacy of the PT
approach must be demonstrated in carefully documented con-
trolled clinical trials. As stressed by J. Scheres from the ECDC at
VoMII, it is unlikely that PT will work as a generic approach.
Probably, certain phages, but not others will work against certain
bacterial infections. At the moment it cannot be predicted what
will be suitable diseases for PT. Since the Soviet experience has
concentrated on diarrhea by Gram-negative bacterial pathogens,
pyogenic and skin infections by Gram-positive bacterial patho-
gens, one might want to target these infections with priority and
leave intracellular infections such as by Mycobacterium tubercu-
losis on a waiting list (Broxmeyer et al., 2002), until the efﬁcacy of
PT has been settled for the more obvious targets. Following
the medical needs, one might want to concentrate on pathogens
that represent the greatest problems with respect to antibiotic
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obacteria (Poirel et al., 2011). Some Klebsiella pneumoniae and E.
coli isolates are already resistant against all known antibiotics and
patients with these pathogens are doomed (http://www.who.int/
patientsafety/implementation/amr/en/). Targeting these infections
with phages might thus address a medical emergency. However,
there are difﬁculties with such approaches from the practical side.
The numbers of affected patients are fortunately still relatively
small, but this presents a dilemma for the development of such
phages. Industrial groups cannot choose them as target because
they represent too small markets for the substantial investment
costs of therapeutic phages (unless something similar to the
Orphan Act for drugs is formulated for PT against these infections).
Since these patients are critically ill, adverse phage side effects are
also more likely and will deter industrial groups for fear of legal
liability. It might be repeating a truism: market forces are only
effective where there is a market. The value of the individual
human life is very high in civilized societies; it remains, however,
‘‘price-less’’ in economic terms. One might therefore predict that
industrial groups are unlikely to go for these targets in the current
framework since the return for investment might be negative and
these groups will go for softer, but more proﬁtable targets. To this
consideration, high regulatory hurdles and patent protection difﬁ-
culties with phages are added which further deter investments in
PT. One might therefore argue that the public health sector must
take the lead in the PT ﬁeld. In the view of the author, organiza-
tions like the the US or European CDC should establish phage
collections for antibiotic-resistant pathogens which soon are likely
to become untreatable in a sizable number of patients. The CDC
should characterize, amplify and purify the relevant phages
according to the safety standards agreed with the FDA. As this is
done for the sake of public health, practical standards will be
developed that can be trusted by the patients (as far they have
conﬁdence in governmental agencies). For cost reasons, it might be
desirable for the CDC to contract service functions to biotech
industries which do the work according to the agreed standards
on a commercial basis. Until the value of PT is established, it is also
desirable that the CDC and the FDA (or other comparable national
or international organizations) supervise the controlled clinical
trials to assure high quality tests. Since the WHO has been involved
in PT trials conducted in Asia during the post World War II period,
leadership from the WHO or the UN Millenium program for global
health might be desirable. Since this clinical research is also in the
interest of the public in times of the announced antibiotic crisis,
the ﬁrst trials should target medical priorities. The lower economic
prospects in treating these infections will necessitate that the ﬁrst
phase is paid by public money. These trials should be conducted for
a couple of bacterial infections so as not to reject PT on the basis of
negative results obtained with one speciﬁc infection. When the
principle and feasibility of PT has been established, the regulatory
and legal framework (including patent rights) is set and the needed
investments are approximately known, one might expect private
companies to take the lead to develop PT approaches for a variety
of bacterial infections. In the current mode, progress in PT is slow and
there are too few interested players involved to expect a timely
answer for a key question: whether PT is an alternative for antibiotic-
resistant bacterial infections. Currently, nobody can conﬁdently
predict whether phages are this alternative. However, the serious-
ness of the threat of antibiotic resistance to the human population
gives this research a high public health priority. Most likely, we
cannot simply wait another 10 years until non-coordinated PT
approaches yield reliable answers; the antibiotic resistance crisis
will simply catch up on us. Even when coordinated at high level
during a time of crisis, research that covers everything from phage
isolation to clinical trial results will take a few years. Even when it
should turn out that PT does not work, knowing this is better thancultivating the illusion that we have a secret weapon in our tool box
against antibiotic-resistant infections where in reality our box is
empty and inventiveness should go into other directions to address
this problem.Acknowledgement
I thank my colleague Wolfram Brueck for reading the
manuscript.
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